Susan H. Eshleman
Affiliations: | Cellular and Molecular Medicine | Johns Hopkins University School of Medicine, Baltimore, MD, United States |
Area:
HIVWebsite:
http://cmm.jhu.edu/index.php?title=Susan_H._EshlemanGoogle:
"Susan H. Eshleman"Mean distance: 21373.2 (cluster 6)
Cross-listing: ID Tree
Children
Sign in to add trainee| Tamara S. Flys | grad student | 2008 | Johns Hopkins |
| Jessica D. Church | grad student | 2009 | Johns Hopkins |
| Iris Chen | grad student | 2011 | Johns Hopkins |
| Jessica M. Fogel | grad student | 2012 | Johns Hopkins |
| Maria M. James | grad student | 2012 | Johns Hopkins |
| Kin Israel Notarte | grad student | 2022-2027 | Johns Hopkins Medical School (Physiology Academic Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hall M, Golubchik T, Bonsall D, et al. (2023) Demographics of sources of HIV-1 transmission in Zambia: a molecular epidemiology analysis in the HPTN 071 PopART study. The Lancet. Microbe |
| Landovitz RJ, Hanscom BS, Clement ME, et al. (2023) Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. The Lancet. Hiv |
| Grant-McAuley W, Piwowar-Manning E, Clarke W, et al. (2023) Population-level analysis of natural control of HIV infection in Zambia and South Africa: HPTN 071 (PopART). Journal of the International Aids Society. 26: e26179 |
| Marzinke MA, Hanscom B, Wang Z, et al. (2023) Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. The Lancet. Hiv |
| Grant-McAuley W, Morgenlander W, Hudelson SE, et al. (2023) Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral load. Frontiers in Immunology. 14: 1178520 |
| Inzaule SC, Siedner MJ, Little SJ, et al. (2023) Recommendations on data sharing in HIV drug resistance research. Plos Medicine. 20: e1004293 |
| Bayan MH, Smalls T, Boudreau A, et al. (2023) Evaluating the impact of point-of-care HIV viral load assessment on linkage to care in Baltimore, MD: a randomized controlled trial. Bmc Infectious Diseases. 23: 570 |
| Skalland T, Ayles H, Bock P, et al. (2023) Community- and individual-level correlates of HIV incidence in HPTN 071 (PopART). Journal of the International Aids Society. 26: e26155 |
| Marzinke MA, Fogel JM, Wang Z, et al. (2023) Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Antimicrobial Agents and Chemotherapy. e0005323 |
| Remien RH, Dacus JD, Farley JE, et al. (2022) HTPN 078: an enhanced case management study to achieve viral suppression among viremic HIV-positive men who have sex with men in the United States. Aids (London, England). 37: 217-231 |